Waterpipe tobacco package warning exposure's impact on risk perceptions and use among young adults in the USA: a longitudinal analysis of the population assessment of tobacco and health study.
non-cigarette tobacco products
packaging and labelling
public policy
Journal
Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
11
06
2018
revised:
23
07
2018
accepted:
09
08
2018
pubmed:
31
8
2018
medline:
29
2
2020
entrez:
31
8
2018
Statut:
ppublish
Résumé
Although Food and Drug Administration (FDA)-mandated waterpipe tobacco warnings were not required until August 2018, some waterpipe tobacco packaging (WTP) sold in the USA, contained warnings prior to this date. We examined the prevalence of WTP warning exposure and whether exposure influenced risk perceptions or use among young adult (aged 18-24 years) current waterpipe users. We used data from waves 1 (2013-2014) and 2 (2014-2015) of the Population Assessment of Tobacco and Health Study, a nationally representative longitudinal study of US adults and youth. We conducted logistic regression analyses to identify factors associated with wave 1 warning exposure, and whether wave 1 WTP warning exposure predicted wave 2 relative risk perceptions and waterpipe use. More than one-third of our sample (35.9%, 95% CI 33.5 to 38.4) reported past-month WTP warning exposure. Exposure was higher among males (adjusted OR (AOR)=1.34, 95% CI 1.04 to 1.72), those who usually do not share the waterpipe (AOR=3.10, 95% CI 1.45 to 6.60), those who purchased waterpipe tobacco (AOR=1.73, 95% CI 1.28 to 2.34), and those with a regular brand (AOR=1.84, 95% CI 1.26 to 2.68). Those exposed to WTP warnings at wave 1 were more likely than those not exposed to perceive waterpipe tobacco to be as or more harmful than cigarettes at wave 2 (AOR=1.35, 95% CI 1.02 to 1.78). There was no association between wave 1 WTP exposure and wave 2 waterpipe use. More than one-third of US young adult current waterpipe users reported WTP warning exposure prior to FDA-mandated warning implementation. Findings suggest the mandated warning may result in high exposure among users; it will be critical to assess exposure's impact on risk perceptions and behaviour after FDA-mandated warnings are implemented.
Sections du résumé
BACKGROUND
Although Food and Drug Administration (FDA)-mandated waterpipe tobacco warnings were not required until August 2018, some waterpipe tobacco packaging (WTP) sold in the USA, contained warnings prior to this date. We examined the prevalence of WTP warning exposure and whether exposure influenced risk perceptions or use among young adult (aged 18-24 years) current waterpipe users.
METHODS
We used data from waves 1 (2013-2014) and 2 (2014-2015) of the Population Assessment of Tobacco and Health Study, a nationally representative longitudinal study of US adults and youth. We conducted logistic regression analyses to identify factors associated with wave 1 warning exposure, and whether wave 1 WTP warning exposure predicted wave 2 relative risk perceptions and waterpipe use.
RESULTS
More than one-third of our sample (35.9%, 95% CI 33.5 to 38.4) reported past-month WTP warning exposure. Exposure was higher among males (adjusted OR (AOR)=1.34, 95% CI 1.04 to 1.72), those who usually do not share the waterpipe (AOR=3.10, 95% CI 1.45 to 6.60), those who purchased waterpipe tobacco (AOR=1.73, 95% CI 1.28 to 2.34), and those with a regular brand (AOR=1.84, 95% CI 1.26 to 2.68). Those exposed to WTP warnings at wave 1 were more likely than those not exposed to perceive waterpipe tobacco to be as or more harmful than cigarettes at wave 2 (AOR=1.35, 95% CI 1.02 to 1.78). There was no association between wave 1 WTP exposure and wave 2 waterpipe use.
CONCLUSIONS
More than one-third of US young adult current waterpipe users reported WTP warning exposure prior to FDA-mandated warning implementation. Findings suggest the mandated warning may result in high exposure among users; it will be critical to assess exposure's impact on risk perceptions and behaviour after FDA-mandated warnings are implemented.
Identifiants
pubmed: 30158209
pii: tobaccocontrol-2018-054562
doi: 10.1136/tobaccocontrol-2018-054562
pmc: PMC6395506
mid: NIHMS1011468
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16-e23Subventions
Organisme : NCI NIH HHS
ID : P50 CA180907
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Tob Control. 2006 Jun;15 Suppl 3:iii19-25
pubmed: 16754942
Int J Public Health. 2016 Jul;61(6):709-715
pubmed: 26971508
Tob Induc Dis. 2018 May 15;16:20
pubmed: 31516420
Asian Pac J Cancer Prev. ;18(9):2533-2540
pubmed: 28952296
Subst Use Misuse. 2015 Jan;50(1):79-89
pubmed: 25268294
Am J Prev Med. 2014 Aug;47(2 Suppl 1):S69-75
pubmed: 25044198
Prev Med. 2016 Jun;87:200-206
pubmed: 26892913
Fed Regist. 2016 May 10;81(90):28973-9106
pubmed: 27192730
Tob Control. 2018 May 16;:
pubmed: 29773707
Drug Alcohol Depend. 2017 Aug 1;177:104-111
pubmed: 28582698
MMWR Morb Mortal Wkly Rep. 2017 Nov 10;66(44):1209-1215
pubmed: 29121001
Drug Alcohol Depend. 2015 Dec 1;157:106-11
pubmed: 26507173
Tob Control. 2015 Mar;24 Suppl 1:i60-i65
pubmed: 25550418
Prev Med. 2017 Sep;102:93-99
pubmed: 28694063
Tob Control. 2017 Jan;26(1):92-97
pubmed: 27165994
Addiction. 2009 Apr;104(4):669-75
pubmed: 19215595
Drug Alcohol Depend. 2011 May 1;115(1-2):131-6
pubmed: 21353750
J Health Commun. 2016 Jul;21(7):818-25
pubmed: 27337629
Health Commun. 2019 Mar;34(3):361-369
pubmed: 29236542
Tob Control. 2010 Jun;19(3):235-9
pubmed: 20501497
Bull World Health Organ. 2000;78(7):902-10
pubmed: 10994263
Biomed Res Int. 2015;2015:745865
pubmed: 26273642
Nicotine Tob Res. 2013 Jan;15(1):93-102
pubmed: 22505660
Tob Control. 2011 Sep;20(5):327-37
pubmed: 21606180
Psychol Health. 2018 Feb;33(2):213-234
pubmed: 28385093
Tob Control. 2019 Jun;28(Suppl 2):s119-s128
pubmed: 29880598
Nicotine Tob Res. 2018 May 3;20(6):731-740
pubmed: 28340148
Nicotine Tob Res. 2015 Jul;17(7):776-83
pubmed: 25239958
Tob Control. 2015 Mar;24 Suppl 1:i13-i21
pubmed: 25618895
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
Nicotine Tob Res. 2014 Mar;16(3):263-9
pubmed: 23946325
Health Psychol. 2014 Nov;33(11):1410-20
pubmed: 24977309
Tob Prev Cessat. 2017 Jun 08;3:116
pubmed: 32432191
Int J Epidemiol. 2017 Feb 1;46(1):32-43
pubmed: 27075769
Tob Control. 2015 Mar;24 Suppl 1:i3-i12
pubmed: 25298368
Addict Behav. 2018 Sep;84:69-74
pubmed: 29627636
Tob Control. 2016 May;25(3):341-54
pubmed: 25948713
Am J Public Health. 2015 Feb;105(2):250-60
pubmed: 25521876
Tob Control. 2015 Mar;24 Suppl 1:i31-i43
pubmed: 25661414
Tob Control. 2018 May;27(3):347-351
pubmed: 28667092
Tob Control. 2006 Dec;15 Suppl 4:iv107-16
pubmed: 17130618
Am J Prev Med. 2007 Mar;32(3):202-9
pubmed: 17296472
Addict Behav. 2017 Apr;67:100-105
pubmed: 28073035
Tob Induc Dis. 2016 May 26;14:17
pubmed: 27231479
Am J Prev Med. 2017 Apr;52(4):507-512
pubmed: 27890515